Event Date/Time: Nov 15, 2004
End Date/Time: Nov 16, 2004
The rising costs of drug development are putting pressure on pharmaceutical companies to reduce clinical attrition and maximize decision-making at the preclinical stage. One of the keys to reducing the cost and time of drug development is early and accurate safety evaluation of candidate drugs. The growing understanding of the toxicity mechanisms is creating an opportunity to develop biomarkers that serve as surrogate endpoints of toxicity at the pre-clinical, clinical, and post-market stages. The Safety/Toxicity Biomarkers meeting will outline specific strategies and case studies necessary to realize and derive value from this information. Safety/Toxicity Biomarkers is the fourth meeting in Cambridge Healthtech Institute's Biomarkers Series. Other meetings include Biomarker Validation, Cancer Biomarkers, and Protein Biomarkers. The meetings for the experts, by the experts!